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I. SUMMARY
Seventeen cases of paralytic poliomyelitis, with 2 deaths, were reported in the 
United States in 1971. This is the lowest annual total reported to the Center for 
Disease Control (CDC) since poliomyelitis surveillance was initiated in 1955. The 
cases were scattered among 12 states. California and Texas with 3 cases each, and 
Montana with 2 cases, were the only states to report more than 1 case. Over half (53%) 
of the cases were in adults and 47% were in pre-school age children. The 3 types' of 
poliovirus were implicated with paralytic disease with almost equal frequency. One 
case was "recipient vaccine-associated"; 8 cases were "contact vaccine-associated."
Eight is the highest annual number of such cases reported to CDC since live, attenuated 
oral poliovirus vaccines became widely used in 1962. None of the persons who con­
tracted paralytic polio in 1971 gave a history of receiving adequate polio vaccinations.
In relation to total doses of oral poliovirus vaccine (OPV) distributed in the 
United States, there has been a statistically significant decrease in the rate of 
"vaccine-associated" paralytic poliomyelitis after 1964 for vaccine recipients p<.0001 
and a statistically significant increase in this rate after 1964 for contacts of vaccine 
recipients, p<.0001. A theory is offered to explain this data in terms of the general 
curtailing of routine immunization for adults after 1964, a shift in emphasis from 
mass immunization campaigns and community-wide programs to routine immunization of 
infants, and a switch from monovalent to trivalent OPV.
The 1971 National Immunization Survey showed a leveling off of the downward trend 
in the percent of pre-school children who received at least 3 doses of oral poliovirus 
vaccine or at least 3 doses of inactivated poliovaccine. Nevertheless, 45.7% of the 
1-4 year-olds in the poverty areas of United States Central Cities with populations 
greater than 250,000 did not receive as many as 3 doses of either type of poliovaccine 
and 14.0% received no poliovaccine.
II. EPIDEMIOLOGY OF POLIOMYELITIS IN 1971
This 17th annual report of poliomyelitis surveillance, published by the Neuro­
tropic Diseases Unit, CDC, summarizes selected epidemiologic and laboratory character­
istics of the reported cases of poliomyelitis for 1971. These data are based upon 
official reports from the states to the Epidemiology Program, CDC.
A. Total Disease Associated with Poliomyelitis, 1971
1. Paralytic Disease. In 1971, the "best available paralytic poliomyelitis case 
count" was 17 cases. This designation, utilized since 1958 as the best available 
representation of the number of cases of paralytic illness of poliovirus etiology, 
includes those clinically and epidemiologically compatible cases known to have residual 
paralysis at 60 days, plus those cases reported initially as paralytic poliomyelitis, 
for which no 60-day report on residual paralysis was available. Limitation of the 
summary count to those cases with proved residual paralysis permits exclusion of cases 
with more transient weakness possibly due to echovirus, Coxsackie virus, or other 
viruses, although not proven as such. All 17 paralytic cases in 1971 have pathologic 
and/or virologic supporting evidence for the diagnosis of poliomyelitis. Follow-up 
reports from 1 to 11 months after onset of illness were submitted for 13 of the 15 
surviving cases. All these reports indicated residual paralysis.
2. Non-Paralytic Disease. No official non-paralytic poliomyelitis case reports 
were received from the states in 1971, although laboratory isolations of poliovirus 
from persons with varying illnesses, including encephalitis and aseptic meningitis 
were reported by several laboratories (see Table 13).
DHEW Publication No. (HSM) 73-8214
B. Epidemiology of Paralytic Cases, 1971
1. Characteristics Of the'Cases. The total number of cases included in the "best 
available paralytic poliomyelitis case count" has declined since this number was first 
tabulated in 1958 (Figure 1). The 17 cases reported for 1971 represents the lowest 
annual total reported to CDC since initiation of surveillance in 1955. In 1971 cases 
occurred throughout the year, with a plurality of 5 occurring in June (Figure 2). The 
classic summer-fall peak, last observed in the early 1960s (Figure 3), has not 
persisted.
Fig. /  "BEST AVAILABLE PARALYTIC POLIOMYELITIS CASE 
COUNT," BY YEAR, UNITED STATES, 1958-1971
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Fig. 2 PARALYTIC POLIOMYELITIS, BY ONSET, U.S.A. ,  1971
Fig. 3 PARALYTIC POLIOMYELITIS CASES, BY MONTH OF ONSET, UNITED STATES, 1962-1971
Geographic distribution of cases by county of residence (Figure M-) shows that 
unlike previous years, there was no large cluster of cases in any one section of the 
country in 1971. Cases were scattered among 12 states. California and Texas with 3 
cases each and Montana with 2 cases, were the only states reporting more than 1 case.
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Fig. 4  PARALYTIC POLIOMYELITIS CASES, BY COUNTY OF RESIDENCE, U.S.A.,
Residual paralysis in the cases parallels that reported for the past 3 years, de­
spite the variable time of follow-up in 1971 (Table 1). Comparison of age distribution 
for the past 10 years is presented in Table 2. In 1971, over half (53%) of the cases 
were in adults and 47% were in pre-school age children.
Three cases were temporally related to travel outside the United States. The 
Massachusetts case occurred in a woman who had recently visited Quebec, Canada, a non­
endemic area. The Cameron County, Texas case and the Nevada case occurred in persons 
who had recently traveled to Mexico, an endemic area; both cases were due to type 1 
poliovirus.
Table 1
PARALYTIC POLIOMYELITIS
BY STATUS OF RESIDUAL PARALYSIS AT 60 DAYS,* 1968-71
1968 1969 1970 1971
Status Cases % Cases % Cases % Cases X
Death 5 10 0 0 2 6 2 12
Severe residual 8 17 4 22 1 3 2 12
Significant residual 18 38 11 58 21 66 9 53
Minor residual 10 21 3 15 3 10 2 12
Unknown 7 14 1 5 6 15 2 12
Total 48 100 19 100 33 100 17 101
* In 1971, status of residual paralysis is based on 1 to 11 month follow-up 
reports
Table 2
PARALYTIC POLIOMYELITIS CASES, BY AGE GROUP, 1962-71
1962 1963 1964 1965 1966 1967 1968 1969 1970 1971
# % # % // 7. // % # % # % # % // % # % // X
0-4 338 49 165 49 38 42 31 51 79 77 25 61 31 65 9 46 30 97 8 47
5-9 139 20 60 18 16 17 10 16 10 10 2 5 3 6 2 11 2 6 0 -
10-14 70 10 38 11 7 8 7 11 3 3 0 - 4 9 1 5 0 - 0 -
15-19 26 4 15 4 8 9 2 3 1 1 1 2 1 2 4 22 0 - 0 -
20-29 52 8 24 7 7 4 4 7 3 3 4 10 4 8 0 - 0 - 3 18
30-39 36 5 18 5 7 8 3 5 5 5 7 17 2 4 2 11 0 - 5 29
40+ 22 3 8 2 11 12 4 7 1 1 2 5 3 6 1 5 1 3 1 6
Unkn. 8 1 8 2 0 - 0 - 0 - 0 - 0 - 0 - 0
'
0 “ ■
TOTAL 691 336 91 61 102 41 48 19 33 17 100
2. "Type Specific Etiology” 6f PolibvifUS'Associated with 1971 Paralytic Cases. 
The basis for establishing a type specific etiology for the 1971 paralytic cases is 
summarized in Table 3. Of the 17 cases, 6 were confirmed by both viral isolation and 
diagnostic (4 fold) rise or fall in serotype-specific antibody titer. In 2 cases, the 
type specific etiology was indicated by serology alone. Although the presence of an 
enterovirus in the alimentary tract does not constitute proof of an etiologic role, 
isolation of poliovirus from throat washings or stool specimens in the context of 
compatible illness and absence of evidence for another etiology has been accepted by 
the respective states as adequate documentation of etiology, and is included in this 
summary as the probable agent.
Table 3
PARALYTIC POLIOMYELITIS
BY DESIGNATION OF ’"ETIOLOGIC" POLIOVIRUS TYPE:, 1971
Polio­
virus 
Type 1
Polio­
virus 
Type 2
Polio­
virus 
Type 3 Unknown Total
Viral isolation and 
diagnostic serology 1 2 3 0 6
Serology as only
laboratory confirmation 0 2* 0 0 2
Viral isolation as only 
laboratory support 4 2 2 0 8
Diagnosis made on clinical and 
epidemiological basis only—  
no evaluation of etiology 
possible 0 0 0 1 1
Total 5 6 5 1 17
*Includes 1 patient with residual paralysis at 3 months and a detectable 
convalescent titer to only type 2 poliovirus
Thus, 8 cases were designated as to type on the basis of viral isolation only. In 1 
instance, the diagnosis of paralytic poliomyelitis was based on clinical and pathologic 
criteria alone. Comparison of "etiologic" poliovirus types for 1966-1971 (the only 
years in which this method of definition has been used) shows that type 1 poliovirus 
comprises a smaller percentage of all cases in 1971 than was true for the preceding 
5 years (Table 4). Tovn„
PARALYTIC POLIOMYELITIS CASES 
BY "ETIOLOGIC" POLIOVIRUS TYPES, 1966-71
Type 1 TyPe 2 Type 3 Unknown
No. 1 No, % No. % No. % Total Cases
1966 60 59 13 13 6 6 23 22 102
1967 18 44 8 19 7 18 8 19 41
1968 27 56 7 15 4 8 10 21 48
1969 6 32 5 26 4 21 4 21 19
1970 28 85 4 12 1 3 0 0 33
1971 5 29 6 35 5 29 1 6 17
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Tabulation of the 17 paralytic cases by age group and "etiologic" virus type (Table 5) 
shows no significant difference in age distribution of persons with each poliovirus
type.
Table 5
PARALYTIC POLIOMYELITIS CASES 
BY AGE GROUP AND "ETIOLOGIC" POLIOVIRUS TYPE, 1971
____________Poliovirus Type____________
Age Group 1 2 3 Unknown Total
0-4 2 2 4 0 8
5-19 0 0 0 0 0
20-29 1 2 0 0 3
30-39 2 2 1 0 5
40+ 0 0 0 1 1
3. Viral Isolations Associated with 1971 Paralytic Poliomyelitis Cases. The 
number of cases in which viral isolations were attempted and the number in which 
isolation attempts were successful for the period 1961-1971 appear in Table 6 . Samples 
for viral isolation were obtained in a higher percentage of cases in 1970 and in 1971 
than in each of the previous 9 years. This probably reflects a continuing increased 
utilization of laboratory testing to confirm clinical impressions.
Table 6
PARALYTIC POLIOMYELITIS 
BY NUMBER OF SPECIMENS SUBMITTED AND RESULTS 
OF VIRUS ISOLATION ATTEMPTS BY YEAR, 1961-1971
Cases with 
Specimens
Best Available Submitted for 
Paralytic Case Isolation____
Count No. %
1961 829 481 58.0
1962 691 472 68.3
1963 336 242 72.0
1964 91 77 84.6
1965 61 50 81.9
1966 103 82 79.6
1967 40 31 77.5
1968 48 39 81.2
1969 19 16 84.2
1970 33 33 100
1971 17 15 8 8 . 2
% of Specimens
Cases With 
Poliovirus Isolated
Submitted in 
Which Isolation 
SuccessfulNo. % of Cases
382 46.1 79%
408 59.0 8 6%
197 58.6 81%
51 56.0 6 6%
38 62.3 76%
74 71.8 90%
29 72.5 93%
35 72.9 90%
14 73.7 8 8%
31 93.9 94%
14 82.4 93%
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For 1971, 14 stool specimens submitted from 15 cases were positive for poliovirus.
Four cases also had positive throat cultures and poliovirus was isolated from the 
spinal cord of 1 fatal case. A comparison of the frequency of isolation of each polio­
virus type from the annual total of paralytic cases is shown in Table 7 for the years 
1961-1971. In 1971, as only seen before in 1969, the 3 types of virus were isolated 
from paralytic cases with almost equal frequency.
Table 7
PARALYTIC POLIOMYELITIS CASES 
BY TYPE OF POLIOVIRUS ISOLATED 
AND PERCENTAGE OF TOTAL CASES BY YEAR, 1961-1971
Year Type
Number of Isolates Percentage
1 2 3 Unknown i 2 3
1961 231 6 145 0 60.5 1 . 6 37.9
1962 300 8 100 0 73.5 2 . 0 24.5
1963 160 6 31 0 81.2 3.0 15.7
1964 21 6 24 0 41.1 1 1 . 8 47.0
1965 19 8 11 1 50.0 2 1 . 1 28.9
1966 55 13 6 1 74.3 17.6 8 . 1
1967 16 6 7 0 55.2 20.7 24.1
1968 25 7 3 0 71.4 2 0 . 0 8 . 6
1969 5 5 4 0 34.6 34.6 30.8
1970 26 4 1 0 83.9 12.9 3.2
1971 5 4 5 0 35.7 28.6 35.7
C. Association of Immunization with Paralytic Poliomyelitis
1. Paralytic Poliomyelitis in Recent VaCOine Recipients. In July 1964 the Surgeon 
General's Special Advisory Committee on all poliomyelitis vaccine reviewed all cases 
of paralytic disease consistent with poliomyelitis that had occurred within 30 days 
following receipt of all oral poliovirus vaccine (OPV). At that time, 57 cases were 
judged to be compatible with vaccine association by virtue of meeting the following 
criteria:
a. Onset of illness between 4 and 30 days following feeding of the specific 
vaccine, plus onset of paralysis not sooner than 6 days after the feeding.
b. Significant residual lower motor neuron paralysis.
c. Laboratory data not inconsistent with respect to multiplication of the 
vaccine virus fed.
d. No evidence of other motor neuron disease, definite sensory loss, or pro­
gression (or recurrence) of paralytic disease 1 month or more after onset.
The cases reported since 1964 have not been formally reviewed by an advisory 
committee. However, the Neurotropic Diseases Unit continues to use the above criteria 
to determine whether such a case is consistent with vaccine association, recognizing 
that such association does not necessarily imply a causal relationship. The cases 
fulfilling the above criteria are termed recipient vaccine-associated cases. In 1971, 
the 1st case of this type in 3 years, and the 16th such case for the period July 1964 
through December 1971, was reported to CDC. The case was in a .5 month-old boy who 
received type 1, type 3, and type 2 monovalent oral poliovirus vaccine (M0PV-1, M0PV-3. 
and M0PV-2) on April 28, May 26, and July 12, 1971, respectively. Sixteen days afte™ 
oral ingestion of the type 3 vaccine and 4 days after the onset of fever, the boy ^  
developed flaccid paralysis of the right arm. Minor residual disability remained at 8
8
months. Type 3 poliovirus was isolated from a stool specimen collected June 24. The 
isolate was antigenically vaccine-like and "T"+ at 39.5° centigrade, and "T"± at U0.1° 
centigrade. (See Section IIIA "Characterization of Poliovirus Isolations".) Sera 
collected June 24, July 20, and September 28 showed titers to type 3 poliovirus of 1:20, 
and 1:20 and <1:10, respectively. Though low, these titers were interpreted as consis­
tent with multiplication of the vaccine virus fed.
2. Paralytic Poliomyelitis in Contacts of Recent Vaccine Recipients. In addition 
to the group noted above, it has been recognized that cases of paralytic illness have 
also occurred in persons with a history of close relationships to OPV recipients. The 
working definition of these contact vaccine-associated cases has specified that onset 
of illness shall have occurred between 4 and 60 days following feeding of the specific 
vaccine in question to the recipient in contact with the case. In addition, contact 
of the case with the recipient shall have occurred within 30 days prior to the onset 
of illness; criteria b, c, and d in the definition of a "recipient vaccine-associated" 
case also applies. This definition of "contact vaccine-association" does not require 
isolation of a vaccine-like virus from the case. Nevertheless, of the 26 "contact 
vaccine associated" cases reported to CDC from 1965 through 1970, isolation of a 
vaccine-like virus was made from 21 cases. For the other 5, a non-vaccine-like virus 
( 1 case) untested viruses (2 cases) and no virus (2 cases) were identified.
Table 8
Paralytic Disease in Close Contacts of Vaccine Recipients-1971
STATE AGE SEX PRIOR
IMMUN
CONTACT 
Rel' Vacc. 
ship Adm'd.
INTERVAL 
Admin 
to Onset
PT'S
IS0L.
TYPE
AriTieENK”
S RCT 
CHAR.
4-Pold
AB
CHANGE
— rtzz:
DISABIL.
Cal. 33 M 0 Son T0PV 24 days 2 Vacc-like
T(i)39.5°
T(-)40.1°
Yes Significant
Col. 26 F 1-M0PV Son 6 
Daugh­
ter
T0PV 5 days 
7 days
2 Vacc-like 
T(+)39.5° 
T(-)40.1°
Yes Significant
G3. • 4 mos M 0 play­
mate
T0PV 35 days 3 Vacc-like 
T(+)40.1°
Yes Unknown
Iowa 20 M 0 Daugh­
ter
T0PV 19 days 2 Vacc-like 
T(±)39.5° 
T(-)40.1°
No Significant
Ky. 33 M 0 Son T0PV 26 days 3 Vacc-like 
T(+)39.5° 
T(±)40.1°
Yes Significant
Wash. 36 M 1-IPV Son TOPV 27 days 2 Vacc-like 
T(±)40.1°
Yes Unknown
Mont. 3 M 0 bro­
ther
OPV* 10 days No
Cul­
ture
Yes
(type
2 )
Minor
Mont. llmos M 0 play­
mate
TOPV 23 days 1 Non-Vacc-
like
T(+)39.5° 
T(±)40.1°
Not
done
Significant
*The OPV type 
distributed in
was
the
not reported.
: United States
However, 
in 1970
TOPV comprised 97.2% and 98 
and 1971, respectively
. 2% of the OPV
In 1971, 8 "contact vaccine-associated" cases were reported, the highest annual 
figure reported to CDC since live, attenuated vaccine became widely used in 1962 (Table 
8 ). Five of these cases occurred in parents of children who were receiving routine
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oral poliovirus vaccinations. Three cases were in children under 4 years of age who 
had a playmate or sibling who recently ingested vaccine. Six cases had no prior polio 
immunization; 1 had 1 IPV and 1 had 1 MOPV. Trivalent oral poliovirus vaccine (TOPV) 
was the vaccine given to the recipient in the 7 cases where the vaccine type was re­
ported. Since over 97% of the OPV distributed in the United States in 1970 and 1971 
was TOPV, it was presumably thie vaccine given the recipient in the 8th case as well.
The experience of recipients and their contacts with respect to developing vaccine- 
associated paralytic disease can be expressed in terms of rates of cases per million 
doses of vaccine distributed (Table 9). These statistics give a useful basis for 
comparing trends. Such rates are not so useful for describing the risks to recipients 
and their contacts because there are no satisfactory estimates of the number of doses 
actually received and the number of susceptible people who contact vaccine recipients. 
These rates are given for 1961-4- and 1965-71 because following 1964 there was a general 
curtailing of routine immunizations for adults as recommended by the Advisory Committee 
on Immunization Practices, there was a shift in emphasis from mass immunization cam­
paigns and community wide programs to routine immunization of infants, and TOPV became 
the most widely used oral poliovirus vaccine.
Table 9
RATES OF VACCINE-ASSOCIATED PARALYTIC POLIO IN OPV RECIPIENTS AND 
THEIR CONTACTS, UNITED STATES, 1961-71
Est. Doses
Distributed Recipient Recipient Contact Contact
Vaccine Period in Millions Cases Rate/Million Cases Rate/Millii
MOPV-1 {
1961-64 109* 16 0.147 0 0
1965-71 8.69 1 0.115 2 0.230
• MOPV-2 {
1961-64 104* 2 0.019 0 0
1965-71 6.89 0 0 2 0.290
MOPV-3 {
1961-64 105* 39 0.371 3 0.029
1965-71 7.40 6 0.811 0 0
ALL MOPV {
1961-64 318* 57 0.179 3 0.009
1965-71 23.0 7 0.304 4 0.174
TOPV {
1961-64 28.2 5 0.177 0 0
1965-71 157 4 0.025 28 0.178
ALL OPV {
1961-64 346 62 0.179 3 0.009
1965-71 180 11 0.061 34** 0.189
*Sources of distribution data: !State health departments and PHS regional offices
prior to June 1962 and the Biologic Surveillance Unit CDC subsequently 
**Includes 2 cases for which type of vaccine administered to recipient is unknown
In relation to all OPV, there has been a statistically significant decrease in the 
rate after 1964 for vaccine recipients, p<.0001, and a statistically significant 
increase in this rate after 1964 for contacts of vaccine recipients, p<.0001. A theory 
to explain the significant increase in the "contact vaccine-associated" cases after 
1964 should be consistent with the facts that both before and after January 1, 1965, 
the rate of "contact vaccine-associated" cases with all MOPV has been similar to the 
rate of "contact vaccine-associated" cases with TOPV. Further, the theory should be 
consistent with the fact that the increase in contact cases has been marked for both
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children and adults. Accordingly the theory proposed in this report contends that the 
significant increase in contact cases is due to both the shift in emphasis from mass 
immunization campaigns to routine immunization of infants, and to a presumed improve­
ment in recognition of contact cases, an improvement which would be facilitated by the 
reduction in total poliomyelitis cases following the 1961-64 polio immunization 
campaigns. The shift from mass campaigns would increase the number of susceptibles4in 
contact with each case. During mass campaigns, for instance, many contacts of a given 
recipient would themselves have received vaccine. This would either protect them from 
becoming infected with another poliovirus, or if not, and paralysis occurred, wotild 
lead to their being classified as "recipient" rather than as "contact vaccine-associated" 
cases.
The shift to routine immunization of infants has been reflected in progressive 
increases in the percentage of infants under one year of age who have received at least 
one dose of OPV. According to the Annual United States Immunization Surveys conducted 
since 1962 by the Bureau of the Census, the percentage of such infants has steadily 
risen: 11.0%, 1962; 32.3%, 1964; 36.6%, 1965; 45.0%, 1967; 52.4%, 1969; and 60.2%,
1971. Since there is evidence that children under 2 years of age spread poliovirus to 
their contacts more readily than older individuals the increase in the percentage of 
infants receiving OPV might also have contributed to the greater rate of "contact 
vaccine-associated" cases after 1964. In 1971, seven of the eight "contact vaccine- 
associated" cases were in contact with a recipient under 1 year of age. The single 
older recipient was 1% years of age.
The decrease in the rate of "recipient vaccine-associated" cases with all OPV 
appears to be largely due to the general curtailing in late 1964 of routine vaccinations 
of adults. This is supported by the fact that 47 of the 62 (75.8%) recipient cases 
before 1965 were adults compared to none of 11 recipient cases reported 1965-71. Against 
the contention that the switch to TOPV played the major role in reducing the rate of 
"recipient vaccine-associated" cases is the absence before 1965 of a significantly 
different rate of "recipient vaccine-associated" cases with TOPV compared to this rate 
with all MOPV. However, that the switch to TOPV played at least some important role 
in reducing the rate of "recipient vaccine-associated" cases is supported first by, 
the significantly lower recipient rate after January 1, 1965 with TOPV compared with 
all MOPV (p<.02); and second, the evidence presented in Table 10 suggesting that the 
effect of type 3 vaccine poliovirus is significantly modified by the simultaneous 
administration of poliovirus type 1 and 2 in the trivalent vaccine.
Table 10
"CONTACT AND RECIPIENT VACCINE-ASSOCIATED" CASES, BY 
ASSOCIATION WITH THE TYPE 3 POLIOVIRUS IN 
TOPV AND MOPV-3, UNITED STATES 
1965-71
TOPV MOPV-3 TOTAL
"Contact Vaccine- 13* 0 13
Associated" Cases with 
Type 3 poliovirus infection
"Recipient Vaccine- 0** 6*** 6
Associated" Cases with 
Type 3 poliovirus infection
*Vaccine-like poliovirus type 3 was isolated from all 13; vaccine-like poliovirus 
type 1 was also isolated from 1 case 
**There were 4 "TOPV recipient vaccine-associated" cases, 1965-71;
1 was associated with vaccine-like poliovirus 2 ,
1 with "intermediate" strain poliovirus 2 , and 
~ 2 were not associated with any poliovirus type 
***Vaccine-like poliovirus type 3 was isolated from 4 cases
aGard, S. in Poliomyelitis 5th International Poliomyelitis Conference, Copenhagen, 
Denmark, July 26-28, 1960. International Poliomyelitis Congress Philadelphia, J.B. 
Lippincott Co., p. 413, 1961
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The greater association of recipient cases with MOPV-3 in Table 10 is statistically 
significant (p=.0004). It is in instructive to note that in Table 10 a total of 127 
"recipient vaccine-associated" cases due to the type 3 virus in TOPV would be expected 
if this recipient rate were to equal 0.811 cases/million doses, the rate for "recipient 
vaccine-associated" cases with MOPV-3 in 1965-71.
3. "Vaccine Failures". A "vaccine failure" is presently defined as paralytic 
disease attributed to poliovirus infection occurring in an individual having previously 
received an "adequate immunization series." As defined by the Advisory Committee on 
Immunization Practices (ACIP), an "adequate" series consists of 4 or more doses of IPV, 
3 doses of MOPV plus one TOPV, or 3 doses of TOPV at appropriate intervals (See ACIP 
Recommendations in appendix). Five of the 17 reported paralytic cases for 1971 had 
previously received OPV prior to onset of illness (Table 11). These 5 cases bring to 
74 the total number of persons, since 1963, reported to have received at least 1 dose 
of OPV prior to onset of paralytic poliomyelitis. Poliovirus type 1 (21 cases) and 3 
(16 cases) have been more frequently implicated in these patients than poliovirus 2 
(8 cases); the etiologic poliovirus type for the others is unknown. Twenty patients 
received at least one dose of TOPV, but only one of these had received 3 or more doses. 
As noted in the 1969 surveillance report, this child had been shown to be hypogamma- 
globulinemic.
Table 11
PARALYTIC POLIOMYELITIS BY IMMUNIZATION STATUS OF 
ALL WITH HISTORY OF AT LEAST ONE 
IMMUNIZATION, 1971
State Age Sex
Prior
Doses
OPV
Type
Year of 
Last OPV 
Dose
Prior
IPV
Doses
Year of 
Last IPV 
Dose
Virus
Type
Impli­
cated
Residual
Disability
Colo. 26 F 1 MOPV 1962 0 2 Significant
Mont. 3 M 2 UNK 1/69 0 2 Minor
Ohio 5 mos. M 1 MOPV-1 4/71 0 3 Minor
Texas 27 F 1 UNK 2/69 0 1 Severe
Texas 4 mos. M 1 TOPV 5/71 0 3 Minor
Wash. 36 M 0 1 1957 2 UNK
III. LABORATORY STUDIES OF POLIOMYELITIS, 1971
A. Characterization of Poliovirus Isolations, 1971
Laboratory techniques have been employed to differentiate "vaccine-like" 
from "nonvaccine-like" strains of virus isolates. One of these tests, the modified 
Wecker intratypic serodifferentiation test, is based upon certain antigenic character­
istics of the virus strains. Another test, the "temperature marker" ("T" marker), is 
based upon comparison of viral replication at different temperatures. In general, 
strains of poliovirus types 1 and 2 that are antigenically "vaccine-like" are usually 
associated with negative "T" markers, while this association is seen less frequently 
with poliovirus type 3. These tests almost always establish with high probability the 
origin of the virus isolated. However, because certain wild type 3 viruses are 
antigenically "vaccine-like" and because of the known antigenic and "T" marker changes
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which can occur, especially with vaccine type 1 virus, these tests do not definitely 
establish the origin of the virus isolated. Furthermore, these tests do not in any way 
indicate the neurovirulance of the isolated virus.
Laboratory characterization studies were performed by Enteric Virology Unit, Labo­
ratory Division, CDC, on 13 of the 14 poliovirus isolates from the patients with para­
lytic poliomyelitis reported in 1971. The characterizations of the viral isolates on 
the vaccine-associated cases were shown in section IIC; 7 of the 8 were antigenically 
"vaccine-like." Studies on 5 of the 6 viral isolates from the nonvaccine-associated 
cases of paralytic poliomyelitis in 1971 revealed 2 antigenically "vaccine-like" viruses 
(Table 12).
Table 12
CHARACTERIZATION OF VIRAL ISOLATES FROM 
NONVACCINE-ASSOCIATED CASES OF 
PARALYTIC POLIOMYELITIS, 1971
State Age Sex
Polio
Type
Isolated
Characterization Anti­
genic £ RCT 39.5°/40.1°
4-fold
AB
Change
Residual
Disability
Calif. 37 M 1 Nonvaccine-like +/+ No Death
Nevada 7 mos F 1 Untested Presump
tive*
Significant
N.Y. 38 M 1 Nonvaccine-like +/+ Yes Severe
Texas 4 mos M 3 Vaccine-like +/± No Significant
Texas 3 mos F 3 Vaccine-like +/+ Yes Significant
Texas 27 F 1 Nonvaccine-like +/+ No Severe
*0nly 
1 , 2 ,
a late convalescent serum with titers of 1:32, <1 :8 , 
and 3, respectively was available
and <1 : 8 for polio types
B. Poliovirus Isolations 1971
Reports of 130 poliovirus isolations were received from reporting laboratories 
in 29 states for 1971. Nine (47.4%) of the characterized type 1 polioviruses were 
antigenically wild (Table 13); 4 of these were isolated from New York, 3 from Texas,
1 from California and 1 from Montana. Though antigenicity does not definitely establish 
the origin of the virus isolated, it may be significant that, except for Montana,these 
states constitute major ports of entry into the United States from areas where wild 
poliovirus type 1 is endemic. Only 4 (14.3%) of the characterized type 2 viruses and 
none of the studied type 3 viruses were antigenically wild. The association of the 
poliovirus isolation and the disease syndrome as shown in Table 13 may not be etiolo- 
gically important. Many of these isolations were made from patients who were known to 
have recently ingested poliovirus vaccine. Except for almost all the paralytic cases, 
none of the other cases from whom a poliovirus was isolated were officially reported as 
poliomyelitis disease.
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Table 13
POLIOVIRUS ISOLATIONS, BY TYPE AND CLINICAL HISTORY 
UNITED STATES, 1971*
Clinical History
Associated with 
Paralytic Disease
Associated with 
Aseptic Meningitis 
and/or Encephalitis
Type 1
Antigenic Char. . 
Vaccine Wild Untested
Type 2
Antigenic Char. 
Vaccine Wild Untested
Type 3
Antigenic Char. 
Vaccine Wild Untested
0 2** 0 0 0 0
17
Other 9 3 10 19 A 15 9 0 18 87
Unknown 0 0 2 1 o o 0 3 10
Total 10 9***■ 15 26 A**** 26 17 0 23 130
Compilation of polio, aseptic meningitis, enterovirus surveillance and CDC Laboratory Records
**Includes a 1970 case with a polio isolation in 1971 
***From New York (A), Texas (3), California (1) and Montana (1)
****From Arizona (1), Maine (1) and North Carolina (2)
IV. VACCINE DISTRIBUTION AND VACCINATION STATUS OF THE POPULATION 
A. Vaccine Distribution
Two kinds of information indicative of the vaccination status of the United 
States population are available. One is the number of doses of polio vaccine distri­
buted annually in the United States. These data, as summarized for 1962-71 in Table 
14, present not the number of doses administered, but the maximum possible utilization. 
More importantly, these data show quite clearly certain trends in immunization practice.
Table 1A
POLIOMYELITIS VACCINES, NET DOSES (MILLIONS) 
DISTRIBUTED ANNUALLY, UNITED STATES, 1962-71
Poliomyelitis
Vaccine 1962* 1963 196A 1965 1966 1967 1968 1969 1970 1971
Inactivated (IPV) 15.3 19.0 8 .8 7.5 5.5 A.O 2.7 "kick kkk
Live, Oral (OPV)
Monovalent (MOPV)
Type 1 33.1 38.7 2A.9 A.7 1. A 1.3 0.5 0. A .3 .2
Type 2 37.0 3A.2 29.8 3.A 1.3 0.9 0.5 0. A .2 .1
Tvpe 3 13.7 5A.2 28.A 3.7 1. A 1.0 0 .6 0. A .3 .2
Trivalent(TOPV) — A. 2** 2A .0 17.A 2A .0 18.0 23.9 22.5 25.8 25.5
Total 99.1 150.3 115.9 36.7 33.6 25.2 28.2 23.7 26.6 25.9
*July-December (Biologies Surveillance Program began July 1962)
**Production began in mid-1962
***Not shown since fewer than 3 distributors reported
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After 1963 the distribution of IPV steadily declined to the low 1968 level of 
2.7 million doses. Essentially no IPV was available for use in the United States in 
1969. With the introduction of TOPV in 1963, use of MOPV diminished to the 1971 level 
of less than 1/3 of a million doses of each of the 3 types. It should be noted, of 
course, that the raw data on doses are not adjusted- for the number of doses in each 
category required for a primary immunization series. Nevertheless, TOPV is now clearly 
the most widely used vaccine. The overall decrease in total doses of vaccine distri­
buted yearly since 1963 reflects a shift in emphasis from mass immunization campaigns 
and community-wide programs to routine immunization of infants.
B. The 1971 Immunization Survey
A second approach to estimating immunization levels in the population involves 
a sample survey of the history of types and doses of vaccine received.* While this 
questionnaire method is not as accurate as serologic surveillance, it has proved use­
ful in assessing the proportion of the population that can be expected to exhibit 
immunity to poliovirus infection. Table 15 shows the percentages of the population 
by age group that had received at least 3 doses of OPV or at least 3 doses of IPV and 
the percentage with no poliovaccine whatsoever for 1965-1971.
Table 15
POLIOVACCINE IMMUNIZATION STATUS BY AGE GROUP (UNDER 15 YEARS)
UNITED STATES 1965-1971
Percentage with > 3 doses Percentage with no OPV or
of OPV or > 3 doses of IPV IPV Immunization
Age Group Age Group
Year 1-4 5-9 10-14 1-4 5-9 10-14
1965 73.9 89.9 92.1 9.9 3.0 2 . 1
1966 70.2 8 8 .2 90.0 11.3 2.9 2.3
1967 70.9 88.3 89.7 11.7 3.1 2 . 2
1968 68.3 84.9 87.8 10.5 3.3 2 . 2
1969 67.7 83.6 85.7 1 0 . 2 3.2 2.5
1970 65.9 82.3 85.3 1 0 . 8 3.6 2.3
1971 67.3 81.2 83.9 8 . 6 3.3 2 . 6
The decline from 1965-1970 in pre-school age children who received at least 3 doses of 
OPV or at least 3 doses of IPV appears to have leveled off in 1971. The downward trend 
continues in the 5-9 and 10-14 year age groups. The immunization history, by economic 
status and age group under 10, for the United States Central Cities with population 
greater than 250,000 is shown in Table 16. In the poverty areas of the Central Cities, 
45.7% of the 1-4 year age group have received less than 3 doses of either OPV or IPV. 
Even after reaching school age, 26.2% in these areas received fewer than 3 doses of 
either OPV or IPV, and 4.4% have received no polio immunization. These figures illu­
strate where greater immunization efforts are needed.
*United States Immunization Survey-September 1971
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Table 16
POLIOVACCINE IMMUNIZATION STATUS 
IMMUNIZATION HISTORY BY ECONOMIC STATUS AND AGE GROUP 
(UNDER 10) FOR U.S. CENTRAL CITIES WITH POPULATION 
GREATER THAN 250,000, 1971*
Percentage** Percentage with
Population "Inadequately" No IPV or OPV
Age Group (thousands) Immunized Immunization
Poverty Areas 1-4 871 45.7 14.0
5-9 1091 26.2 4.4
Non-Poverty Areas 1-4 2286 34.5 7.7
5-9 2893 18.4 2.7
*Source - United States Immunization Survey, September 1971
**<3 doses of OPV or <3 doses of IPV in acceptable primary series
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RECOMMENDATION OF THE PUBLIC HEALTH SERVICE 
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
POLIOMYELITIS VACCINE
INTRODUCTION
Widespread use of poliovirus vaccines since 1955 has 
resulted in the virtual elimination of paralytic 
poliomyelitis in the United States. To ensure continued 
freedom from the disease, it is necessary to pursue 
regular immunization of all children from early 
infancy.
Paralytic poliomyelitis declined from 18,308 cases 
in 1954 to 32 cases in 1970 and 19 cases in 1971. A 
national survey in 1971 showed that 77 percent of 
individuals 1-19 years old had received at least 3 doses 
of oral poliovirus vaccinc*(OPV), inactivated poliovirus 
vaccine**(IPV), or both.
Nevertheless, low immunization rates still prevail in 
certain disadvantaged urban and rural groups, 
particularly for infants and young children born since 
the mass immunization campaigns conducted between 
1958 and 1962. Most of the cases of paralytic 
poliomyelitis in recent years occurred in these 
populations.
With widespread use of poliovirus vaccine, 
laboratory surveillance of enteroviruses indicates that 
circulation of wild policwiruses has diminished 
markedly. It can be assumed that inapparent infections 
with wild strains will no longer contribute significantly 
to maintaining immunity; therefore, it is essential not 
only to continue active immunization programs for 
infants and children but also to make special efforts to 
raise the low immunization rates existing in certain 
other segments of the population.
POLIOVIRUS VACCINES
Between 1955, when 1PV was introduced, and 1962, 
when live, attenuated vaccines became widely used, 
more than 400 million doses of IPV were distributed in 
the United States. Primary immunization with IPV plus 
regular booster doses provided a high degree of 
protection against paralytic disease.
OPV has almost completely replaced IPV in this 
country because it is easier to administer and produces 
an immune response like that induced by natural 
poliovirus infection.
Monovalent OPV types 1,2, and 3 were widely used 
in the United States beginning in 1961, but they have 
generally been supplanted by trivalent OPV because of 
greater simplicity in scheduling and recordkeeping.
A primary series of 3 adequately spaced doses of
‘ Official names: (!) Poliovirus Vaccine, Live. Oral, Type 1, 
(2) Poliovirus Vaccine, Live, Oral, Type 2, (3) Poliovirus Vac­
cine, Live, Oral. Type 3, (4) Poliovirus Vaccine, Live, Oral. 
Trivalent.
‘ ♦Official name: Poliomyelitis Vaccine.
trivalent OPV will produce an immune response to the 
3 poliovirus types in well over 90 percent of recipients.
Very rarely, paralysis has occurred in recipients of 
OPV or in their close contacts within 2 months of its 
administration. During 1963-70, about 147 million 
doses of trivalent OPV were distributed in the United 
States. In the same 8-year period, 9 cases of 
“ vaccine-associated” paralysis in recipients 
(0.06/million doses distributed) and 21 in contacts of 
recipients (0.14/million doses distributed) were 
reported.
In 1972, OPV produced in the WI-38 strain of 
human diploid cells was licensed in the United States. 
This vaccine is considered to be equivalent in safety 
and effectiveness to vaccine produced in primary rhesus 
monke> kidney cell culture.
VACCINE USAGE
Trivalent O PV —Primary Im m unization
infants; The 3-dose immunization series should be 
started at 6-12 weeks of age, commonly with the first 
dose of DTP. The second dose should be given not less 
than 6 and preferably 8 weeks later. The third dose is an 
integral part of primary immunization and should be 
administered 8-12 months after the second dose.
Children and adolescents: For unimmunized children 
and adolescents through high school age, the primary 
series is 3 doses. The first 2 should be given 6-8 weeks 
apart, and the third, 8 12 months after the second. If 
circumstances do not permit the optimal interval 
between the second and third doses, the third may be 
given as early as 6 weeks after the second.
Adults: Routine poliomyelitis immunization for
adults residing in the continental United States is not 
necessary because of the extreme unlikelihood of 
exposure. However, an unimmunized adult at increased 
risk through contact with a known case or travel to areas 
where polio is epidemic or occurs regularly should 
receive trivalent OPV as indicated for children and 
adolescents. Persons employed in hospitals, medical 
laboratories, and sanitation facilities might also be at 
increased risk, especially if poliomyelitis is occurring in 
the area.
Pregnancy is not an indication for vaccine admini­
stration, nor is it a contraindication when protection is 
required.
M onovalent O P V -P rim ary Im m unization
An alternative primary immunization is 1 dose of 
each of the 3 types of monovalent OPV given at 6 8 
week intervals. A dose of trivalent OPV should be given
8-12 months after the third dose of monovalent OPV 
to ensure adequate responses to all poliovirus types.
OPV—Booster Doses
Entering school: On entering kindergarten or first 
grade, all children who have completed the primary 
series of OPV should be given a single dose of trivalent 
OPV; others should complete the primary series.
There is no indication for routine booster doses of 
OPV beyond that given at the time of entering school.
Increased risk: A single dose of trivalent OPV can be 
administered to anyone who has completed the full 
primary series because of travel or occupational hazard 
as described above. The need for such an additional dose 
has not been established, but if there is uncertainty 
about the adequacy of existing protection, a single dose 
of trivalent OPV should be given.
Contraindications
A ltered  immune states: Infection with live,
attenuated polioviruses might be potentiated by severe 
underlying diseases, such as leukemia, lymphoma, or 
generalized malignancy, or by lowered resistance, such as 
from therapy with steroids, alkylating drugs, anti­
metabolites, or radiation; therefore, vaccination of such 
patients should be avoided.
EPIDEM IC CONTROL
For operational purposes in the United States, an 
“epidemic” of poliomyelitis is defined as 2 or more cases 
caused by the same poliovirus type and occurring within 
a 4-week period in a circumscribed population, such as 
that of a city, county, or a metropolitan area. An 
epidemic can be controlled with either trivalent OPV. or. 
after identification of the responsible type of poliovirus, 
homotypic monovalent OPV. Within the epidemic area, 
all persons over 6 weeks of age who have not been 
completely immunized or whose immunization status is 
unknown should promptly receive OPV.
SIM U LTA N EO U S A D M INISTRATIO N OF  
LIVE V IR U S VACCINES
There are obvious practical advantages to 
ad m in iste rin g  2 or more live virus vaccines 
simultaneously. Data from specific investigations are not 
yet sufficient to develop comprehensive recommenda­
tions on simultaneous use, but a summary of current ex­
perience, attitudes, and practices provides useful guid­
ance.
It has been generally recommended that live virus 
vaccines be given at least 1 month apart whenever 
possible—the rationale for this being that more frequent 
and severe adverse reactions as well as diminished 
antibody responses otherwise might result. Field 
observations indicate, however, that with simultaneous 
administration of certain live virus vaccines, results of 
this type have been minimal or absent.
If the theoretically desirable I-month interval is not 
feasible, as with the threat of concurrent exposures or 
disruption of immunization programs, the vaccines 
should preferably be given on the same day-at different 
sites for parenteral products. An interval of about 2 
days to 2 weeks should be avoided because interference 
between the vaccine viruses is most likely then.
Published: Supplement to the Poliomyelitis Surveillance Unit 
Report No. 285, 1964; revised MMWR Vol 16 No. 33, 1967; 
revised Vol 18 No. 43-Supp 1969: revised Vol 21 No. 25-Supp 
1972.
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STATE EPIDEMIOLOGISTS
Key to all disease surveillance activities are those in each State who serve the function as State 
epidemiologists. Responsible for the collection, interpretation and transmission of data and epidemiologic 
information from their individual States, the State epidemiologists perform a most vital role. Their major 
contributions to the evolution of this report are gratefully acknowledged.
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